1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Eusol Biotech Co.,Ltd.

Eusol Biotech Co.,Ltd.

6652.TWO
Eusol Biotech Co.,Ltd.TW flagTaipei Exchange
1.96
TWD
- -
- -
268.52MMarket Cap
Eusol Biotech Co.,Ltd.
6652.TWO
(Taipei Exchange)

Recent

price

1.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1,089.55
-1.17
-1.96
-1.57
-0.86
-0.91
-0.92
-0.13
-0.38
-0.22
- -
Basic EPS, GAAP
-947.42
-1.23
-2.75
-2.32
-0.75
-0.73
-0.67
-0.39
-0.31
-0.24
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2,303.43
3.39
2.33
0.93
0.06
-0.81
-0.78
-0.89
-1.1
-1.3
- -
Book Value per Share
2,166.8
3.26
3.6
3.01
2.18
1.48
2.78
3.08
2.93
2.67
- -
Tangible Book Value per Share
- -
84
111
124
125
125
134
137
137
139
- -
Basic Weighted Avg Shares
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
2
Sales/Revenue/Turnover
- -
- -
-32,118.66
- -
- -
- -
- -
- -
- -
- -
-2,267.45
Operating Margin (%)
14
13
24
24
29
29
28
23
4
4
3
Depreciation Expense
-87
-99
-217
-194
-107
-114
-123
-18
-52
-31
-40
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-31,666.91
- -
- -
- -
- -
- -
- -
- -
-1,945.88
Profit Margin (%)
89
191
299
260
160
85
285
404
396
367
318
Working Capital
89
85
81
- -
8
4
1
4
2
- -
9
LT Debt
184
287
523
482
366
261
434
422
401
370
330
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-41.97
-79.79
-104.07
-176.13
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.76%
8.04%
-10.91%
Free Cash Flow
7.66%
-15.81%
6.07%
Net Income, GAAP
18.07%
19.32%
32.3%
Sales/Revenue/Turnover
- -
- -
202.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.38
2024
- -
- -
- -
- -
-0.22
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Lexicon Pharmaceuticals, Inc. (LXRX)
Accustem Sciences Inc. (ACUT)
Biovica International AB (publ) (BIOVIC-B.ST)
Vanta Bioscience Limited (VANTABIO.BO)
Timber Pharmaceuticals, Inc. (TMBR)
Probi AB (publ) (PBBIF)
Business
Eusol Biotech Co., Ltd. (6652.TWO) develops biopharmaceutical products focused on neurological disorders, sleep dysfunction, spinal cord and peripheral nerve injuries, and related therapeutic areas. The company offers a pipeline of proprietary protein and small molecule drugs including ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury and peripheral nerve repair; SM-1, a 3-in-1 combination sleeping aid capsule; EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, an anti-inflammatory agent for rheumatology; and EA2501, an anticoagulation drug; alongside preparations for licensing approved medicines, medical devices, and co-developing 505(b)(2) new drugs with pharmaceutical partners. In addition, Eusol Biotech markets licensed pharmaceutical products such as Daehwa Yipainning (easy pain reliever) tablets in orange and white formulations from Daehwa Pharmaceutical. Founded in 1994 and headquartered in Taipei, Taiwan, the company operates primarily in the biotechnology and pharmaceuticals sector, targeting healthcare providers and patients in Taiwan and select Asian markets. Recent developments include securing distribution rights in May 2025 for Daehwa Pharmaceutical's pain relief drug Yipainning from South Korea; forming a January 2025 alliance with Ying Shuo to develop a novel anticoagulant, positioning for first-to-file generic opportunities; and announcing positive Phase 3 clinical trial results in October 2024 for ES135 in spinal cord injury treatment. These initiatives expand Eusol Biotech's portfolio beyond core R&D into strategic partnerships, in-licensing, and commercialization, while advancing exploratory trials for ES135 in carpal tunnel syndrome. The company maintains GMP processes for drug production and focuses on unmet needs in neurology, psychiatry, and sleep medicine.